% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • dont_ask_me_dont_tell_you dont_ask_me_dont_tell_you Jan 27, 2013 12:57 PM Flag

    Biotechs are always a guess but -


    if you do your DD and research, you can locate those who have a much better shot at approval than others. In the case of CLSN, phase 2 results were eye opening to say the least. If you are going to gamble on a biotech, the odds are in our favor with CLSN.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • b.oneil1 Jan 27, 2013 2:04 PM Flag

      So obviously you dont know what you're talking about. NO PHASE 2

    • Wow, great DD, CLSN didn't do any P2 trials, they went straight from P1 to P3.

      • 1 Reply to dreggy
      • So you have nothing to go on but a P1 trial?
        That explains why everyone is beaming with confidence.))

        So, Turg lied? That can't be good.

        "Celsion Plans to Launch Phase II Program to Study ThermoDox(R) in Combination with RFA for Colorectal Liver Metastases

        "COLUMBIA, Md., March 1 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) today announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti , Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care at the Montefiore Medical Center and Albert Einstein College of Medicine in New York City, will serve as Principal Investigator for the study. In addition to Montefiore Medical Center, at least 2 other leading research institutions from North America and the Asia Pacific region (including Japan) will be included in the Phase II study, which is expected to commence in the second half of 2010. The study is meant to address the growing unmet medical need of colorectal liver metastases, which is globally prevalent and is currently treated by radiofrequency ablation.
        "Celsion Corporation first began studying ThermoDox in combination with RFA for liver metastases in a Phase I safety study of 24-patients"

    • The P2 results are no indicator of future success.
      P2s are designed for a positive outcome.

      I attended a corporate conference where a presenting company showed a Parkinson's patient with a walker and then after treatment in a P2 trial the patient was doing back flips, well almost. When the subsequent trial data was released, efficacy wasn't better than the placebo.

      When there is so much hype as there is with CLSN, expect failure.
      That rule rarely fails.

      Do you really think that all the idiots on this board will make a bundle?
      There's almost no chance of that.

      Is anybody waiting to buy after the data?
      Just about everyone is looking to sell all or some of their shares after the data.
      What does that tell you?
      What do you think will happen to the pps if the data is good and the MM opens the stock with a gap up?

1.10-0.03(-2.65%)Feb 10 4:00 PMEST